Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Hadley

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
MLO: Medical Laboratory Observer|September 16, 2004
Band counts rouse passionsJames Hadley
The Journal of Allergy and Clinical Immunology. in Practice|March 11, 2014
Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitisWilliam E Berger, Shailen Shah, Phil Lieberman, et al.
Current Sports Medicine Reports|July 8, 2022
The Current Accuracy, Cost-Effectiveness, and Uses of Musculoskeletal Telehealth and Telerehabilitation ServicesKatherine Rennie, Charles Taylor, Anna Chiara Corriero, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|February 5, 2005
Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitisEli O Meltzer, James Hadley, Michael Blaiss, et al.
International Archives of Allergy and Immunology|May 9, 2013
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysisEli Meltzer, Paul Ratner, Claus Bachert, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
MLO: Medical Laboratory Observer|September 16, 2004
Band counts rouse passionsJames Hadley
The Journal of Allergy and Clinical Immunology. in Practice|March 11, 2014
Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitisWilliam E Berger, Shailen Shah, Phil Lieberman, et al.
Current Sports Medicine Reports|July 8, 2022
The Current Accuracy, Cost-Effectiveness, and Uses of Musculoskeletal Telehealth and Telerehabilitation ServicesKatherine Rennie, Charles Taylor, Anna Chiara Corriero, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|February 5, 2005
Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitisEli O Meltzer, James Hadley, Michael Blaiss, et al.
International Archives of Allergy and Immunology|May 9, 2013
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysisEli Meltzer, Paul Ratner, Claus Bachert, et al.
Pageof 1